{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-067836","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.101550+00:00","generated_at":"2026-06-01T06:56:06.728655+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Structure Therapeutics updates risk factors and GLP-1 agonist market data in 8-K filing","bullets":["Updated disclosure: six GLP-1R agonists generated ~$35.9B in 2023 sales, projected to reach $85.9B by 2027.","Added risk factors include NHP shortage, BIOSECURE Act potential impact on WuXi STA supply, and clinical trial risks.","Phase 2a obesity cohort for GSBR-1290 showed 6.2% placebo-adjusted weight loss at 12 weeks in June 2024.","Company plans to submit IND for Phase 2b chronic weight management study of GSBR-1290 in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-067836","json":"https://secwatch.observer/filing/0001104659-24-067836.json","markdown":"https://secwatch.observer/filing/0001104659-24-067836.md","text":"https://secwatch.observer/filing/0001104659-24-067836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924067836/0001104659-24-067836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924067836/tm2414821d8_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:56:06.728655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}